Semaglutide, known by brand names such as Ozempic and Wegovy, is widely used due to its effectiveness
Comparing the slopes of the relationships between plasma glucose and glucagon in the absence and presence of REMD2.59 suggests that glucagon secretion in vivo is reduced by 70%
While effective for general users, it lacks the tailored focus on GLP-1-specific nutrition metrics like fiber and protein intake
About CT-996 CT-996 is an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity
Reviewing trends together can help guide next steps, whether thats addressing side effects, adjusting habits, or considering dose changes
GLP-1s is common shorthand for a class of drugs that includes both glucagon-like peptide 1 receptor agonists and GIP/GLP-1s, which also target a second receptor, the glucose-dependent insulinotropic polypeptide receptor